Edition:
United States

BioInvent International AB (BINV.ST)

BINV.ST on Stockholm Stock Exchange

2.30SEK
24 May 2017
Change (% chg)

0.01kr (+0.44%)
Prev Close
2.29kr
Open
2.29kr
Day's High
2.33kr
Day's Low
2.27kr
Volume
212,429
Avg. Vol
839,536
52-wk High
3.53kr
52-wk Low
1.77kr

BINV.ST

Chart for BINV.ST

About

BioInvent International AB (BioInvent) is a Sweden-based biopharmaceutical company. The Company is engaged in the research and development of antibody-based drugs for the treatment of diseases, such as thrombosis, cancer and acute coronary artery disease. Its product range includes human antibodies, such as TB-402, TB-403,... (more)
No analyst recommendations are available for BINV.ST.

Overall

Beta: 0.48
Market Cap(Mil.): kr700.80
Shares Outstanding(Mil.): 304.70
Dividend: --
Yield (%): --

Financials

  BINV.ST Industry Sector
P/E (TTM): -- 138.86 17.42
EPS (TTM): -0.29 -- --
ROI: -71.69 2.17 -5.45
ROE: -71.69 0.04 -4.73

BRIEF-BioInvent swings to net loss in Q1

* Q1 earnings after tax SEK -22 (0.3) million Source text for Eikon: Further company coverage: (Stockholm Newsroom)

May 17 2017

BRIEF-Bioinvent Q4 net loss narrows

* Q4 profit/loss after tax: sek -7.3 (-21) million Source text for Eikon: Further company coverage: (Reporting by Stockholm Newsroom)

Feb 15 2017

BRIEF-Bioinvent cancels extraordinary general meeting

* Says Board intends instead to present the proposal for an incentive program for shareholder approval at the Annual General Meeting to be held on May 17, 2017. Source text for Eikon: Further company coverage: (Stockholm Newsroom)

Jan 23 2017

BRIEF-Bioinvent's partner ThromboGenics initiates phase II study

* Bioinvent's collaboration partner ThromboGenics initiates phase II study with the drug candidate THR-317

Jan 10 2017

More From Around the Web

Earnings vs. Estimates